Wednesday, April 24, 2024
MARKET UPDATE
Advertisement Topt

TheCable

Advertisement lead

Nigeria using remdesivir for COVID-19 patients, says Ehanire

Nigeria using remdesivir for COVID-19 patients, says Ehanire
May 05
14:51 2020

Osagie Ehanire, minister of health, says Nigeria has started using remdesivir, an anti-retroviral drug, in managing COVID-19 patients.

Addressing members of the house of representatives on Tuesday, Ehanire said the drug has been administered to patients in Lagos state.

He, however, did not say the outcome of the treatment.

“We have been using that (remdesivir); we have tried that in Lagos too,” he said.

Advertisement

“So, we have tried the antiretroviral drug to see what effect it has.”

The minister said the drug, originally developed as a potential treatment for Ebola, is one of the options which Nigeria has adopted in treating COVID-19 patients.

But he said no herbal medicine has so far been approved for the disease.

Advertisement

TheCable had reported how 150 patients recovered after being treated with the experimental anti-retroviral drug.

Gilead Sciences, the pharmaceutical company that developed the drug, said it was found to be effective on the patients during the trial which began in February.

But it added that the optimal duration of treatment is still being studied in ongoing clinical trials.

The US Food and Drug Administration (FDA) has approved the use of the drug for hospitalised COVID-19 patients.

Advertisement

The World Health Organisation (WHO) has not approved any drug or vaccine for COVID-19.

Click on the link below to join TheCable Channel on WhatsApp for your Breaking News, Business Analysis, Politics, Fact Check, Sports and Entertainment News!

1 Comment

  1. Ozabho
    Ozabho May 05, 19:25

    When will the minister tell us the result of testing the herbal drug developed in Catholic Monastery at Ewu in Edo State?
    Nigeria must not miss this godsend opportunity to step big into the lucrative pharmaceutical industry.

    Reply to this comment

Write a Comment

error: Content is protected from copying.